Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

Source :: Plus Company Updates. March 12, 2020
Publication Year :: 2020
Abstract: GAITHERSBURG: Emergent BioSolutions Inc has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated development of two product candidates for the treatment and prevention [...]

Subjects :: United States. Food and Drug Administration
Anthrax vaccines
Intravenous immunoglobulins
Smallpox vaccines
Drug approval
Botulism
Vaccines
Biological products
Vaccinia
Backup software
Production management
Diseases
Infrastructure (Economics)
General interest
News, opinion and commentary

Tools